{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009428","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.371942+00:00","generated_at":"2026-05-15T16:35:07.751700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026","bullets":["Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.","Cash and equivalents $14.9M at Dec 31, 2025, increased to $24.7M post-ATM offering in Q1 2026.","Phase 3 study of LPCN 1154 (PPD) completed last patient visit; topline data expected early April 2026.","R&D expenses rose to $8.6M from $7.4M on higher clinical study costs; G&A down to $3.8M.","Company plans 505(b)(2) NDA submission for LPCN 1154 in mid-2026 if Phase 3 successful."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009428","json":"https://secwatch.observer/filing/0001493152-26-009428.json","markdown":"https://secwatch.observer/filing/0001493152-26-009428.md","text":"https://secwatch.observer/filing/0001493152-26-009428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/0001493152-26-009428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:35:07.751700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}